Cargando…
Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung cancer (NSCLC), which is resistant to conventional chemotherapy and radiotherapy with a poor prognosis. The MET inhibitor may be effective for the patients with MET exon 14 skipping mutation. This mutation was...
Autores principales: | Dai, Gangyi, He, Lang, Yan, Qin, Li, Yamao, Huang, Yuandong, Li, Bin, Wang, Guoping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348826/ https://www.ncbi.nlm.nih.gov/pubmed/37456237 http://dx.doi.org/10.3389/fonc.2023.1167516 |
Ejemplares similares
-
Anlotinib Combined With Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review
por: Li, Jing, et al.
Publicado: (2021) -
Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review
por: Wen, Yingmei, et al.
Publicado: (2023) -
Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study
por: Chen, Xiaofeng, et al.
Publicado: (2022) -
MET alterations in advanced pulmonary sarcomatoid carcinoma
por: Gong, Chen, et al.
Publicado: (2022) -
Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review
por: Liu, Zichang, et al.
Publicado: (2023)